Bretton Fund Exits Revvity After 28.5% Loss, Shares at $98.49
Bretton Fund's Q4 2025 letter revealed a -28.5% loss and led to its exit of Revvity after management spent a Covid windfall on overpriced acquisitions. Revvity shares closed at $98.49 on March 4 2026, have declined 13% over 52 weeks and carry an $11.17 billion market cap.
1. Bretton Fund Exits Revvity Position
In its Q4 2025 investor letter, Bretton Fund reported a -28.5% loss from its Revvity holding, attributing the decline to management’s use of Covid-era cash for overpriced acquisitions and the divestiture of its food testing division. The firm cited stalled pharma research spending and significant FDA budget cuts for science as factors behind the decision to liquidate the position.
2. Revvity Share Performance and Market Cap
Revvity shares closed at $98.49 on March 4 2026, marking a 1.03% loss over the past month and a 13% drop over the last 52 weeks. The company’s market capitalization stands at $11.17 billion, reflecting investor concerns over its recent strategic choices.
3. Hedge Fund Interest Rising Despite Exit
Despite Bretton Fund’s exit, hedge fund interest in Revvity increased, with 35 portfolios holding the stock at the end of Q4 2025, up from 22 in the previous quarter. The rise suggests some investors still see long-term potential in the health sciences platform amid broader AI and personalized medicine trends.